Trial Profile
A Pilot Multicenter Phase I/II Trial of RAD001 in Patients With Recurrent Glioblastoma Multiforme.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Glioblastoma
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Novartis
- 26 Jul 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 26 Jul 2011 Actual trial end date changed from 1 Dec 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
- 26 Jul 2011 Actual initiation date changed from 1 Oct 2006 to 1 Aug 2007 as reported by ClinicalTrials.gov.